
Patients For Affordable Drugs is the ONLY bipartisan patient advocacy group focused exclusively on lowering drug prices. And we do so without funding from the pharmaceutical industry. Learn more: PatientsForAffordableDrugs.o…

Patients For Affordable Drugs is the only independent national patient org fighting to achieve policy changes to lower the price of #prescriptiondrugs.

Patients For Affordable Drugs is the ONLY bipartisan patient advocacy group focused exclusively on lowering drug prices. And we do so without funding from the pharmaceutical industry. Learn more: PatientsForAffordableDrugs.o…

We don't take a dime from Big Pharma. Period. At Patients For Affordable Drugs, our independence means we can hold drug companies accountable without conflicts of interest or strings attached. Our priority is patients. Learn more and get involved: P4AD.ORG

Diagnosed with Crohn's disease at 11, Kevin relies on Rinvoq to manage his condition. But with a list price of more than $7,000 a month, the cost is a constant struggle. He's faced bills of up to $2,000 out of pocket, gone without medication because he couldn't afford it, and spent hours fighting for refills instead of focusing on school. Without consistent access to treatment, he's never achieved full remission. As Kevin puts it, “It is indescribable being a twenty-something that can't keep up with my friends.” Competition from lower-cost alternatives could help bring down the price of drugs like Rinvoq. But when drug companies use the patent system to delay competition, patients like Kevin are left paying the price. No one should have to sacrifice their health, education, or future to afford the prescription drugs they need.

During yesterday’s @PunchbowlNews briefing, P4AD CEO Merith Basey challenged the idea that we have to choose between pharmaceutical innovation and affordable prescription drugs. “Patients need innovation, but it doesn't have to be either or.” We need a balanced system that includes both groundbreaking treatments and prescription drug prices that people can afford. To learn more about how you can get involved in this movement, visit P4AD.ORG

Have you or someone in your family struggled to afford prescription medication? Have you had to stop taking your prescription drugs due to cost? You’re not alone, and your story matters. At Patients For Affordable Drugs, we help patients share their experiences, speak out about high drug prices, and advocate for change. Visit P4AD.ORG to share your story and learn more.

P4AD CEO Merith Basey joined a Punchbowl News briefing with health policy leaders to discuss prescription drug access and affordability. Alongside Prime Therapeutics and the Biosimilars Council, Merith shared perspectives on the policies and challenges shaping patients’ ability to access affordable prescription drugs. At P4AD, we know that drugs don’t work if people can’t afford them. That’s why we continue bringing the patient perspective to conversations about the future of prescription drug affordability.

Cystic fibrosis families know that the cost of medication can be the difference between life and death for patients with CF. No parent should have to live in fear that their child won't be able to access the prescription drugs they need to survive. Visit P4AD.ORG and learn how advocates like Don are sharing their experiences with high drug costs to create policy change and lower drug prices.

This Thursday, P4AD CEO Merith Basey will join health policy leaders for a breakfast briefing on prescription drug access and affordability. Moderated by @PunchbowlNews Senior Health Policy Reporter @PeterSullivan4, the discussion will feature Merith alongside the President and CEO of Prime Therapeutics, and the Executive Director of the Biosimilars Council and SVP of Policy at the Association for Accessible Medicines. If you’d like to attend the briefing in-person, RSVP here: tinyurl.com/34wkemkj

Following the 2026 midterm elections and the prominence of healthcare and prescription drug affordability as a top concern, Patients For Affordable Drugs CEO Merith Basey released the following statement:

CMS published the final rule for the Medicare Drug Price Negotiation Program, codifying policies in the guidance documents while instituting multiple P4AD-supported changes from our comments submitted on the proposed rule in August.

Brand-name drug companies manipulate the patent system to keep drug prices high. One of the tactics they use is called “patent thickets”. This is when big drug companies secure as many patents as possible on a single drug in order to artificially prolong monopoly periods and deter competitors. These “thickets” can prevent competition for years on end, keeping prices high for patients. Want to learn more about Big Pharma’s anticompetitive practices and fight against them? Visit PatientsPushForCompetition.O…

👻 Drug unaffordability is quite scary 👻 This spooky season, use your voice against Big Pharma’s greed! By amplifying your voice, we aim to drive meaningful policy change that will lower drug costs for everyone. Join our community today! actionnetwork.org/forms/base…

“What happens if I have a medical emergency? How is that going to impact my family? Where am I going to get the money?” This is the harsh reality patient advocate, Kris Garcia, lives with every day. Kris has a bleeding disorder, so it is essential that he takes his medications as prescribed. However, one vial of those medications costs $10,000. As a father of four, the financial burden goes beyond his own health. It's the constant worry of how he can afford the treatment he needs while making sure his family is taken care of. No one should have to choose between affording the medications they need and their family's financial security. If you want to learn more about what you can do so families like Kris don’t have to struggle everyday, visit P4AD.ORG @rmpbs

Americans pay four to eight times more for the same brand-name drugs than patients in other wealthy countries. Drug companies make profits selling these medicines around the world. But in the U.S., they can set exorbitant launch prices and abuse the patent system to keep lower-cost competition off the market. P4AD’s Merith Basey explains some of the reasons Americans are paying so much more.

Melissa advocates for lower drug prices on behalf of her young children, Victor and Nina, who live with Epilepsy. Do you or someone you love struggle with your prescription drug costs? Join our growing movement of patients and caregivers using their voices to fight for policy change, visit P4AD.ORG to get involved today.

We're currently in the lead for a 2026 Anthem Award, but the competition is catching up! Selected from more than 2,500 projects, we’re proud to see this work recognized alongside other campaigns driving social impact. But we need your help! Voting is open through October 29. Don’t forget to verify your email after voting to make sure your vote counts! Thank you for helping us keep up the fight for lower prescription drug prices! #AnthemAwards @anthemawards celebrate.anthemawards.com/P…